Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers.
about
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureusAntimicrobial pharmacodynamics: critical interactions of 'bug and drug'.Adverse events in healthy individuals and MDR-TB contacts treated with anti-tuberculosis drugs potentially effective for preventing development of MDR-TB: a systematic review.Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults.Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.Pharmacokinetics and pharmacodynamics of antibacterial agents.Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin.Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects.Levofloxacin in the treatment of community-acquired pneumonia.Antibiotic dosing in critically ill patients with acute kidney injury.Fluoroquinolone disposition: identification of the contribution of renal secretory and reabsorptive drug transporters.Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples.Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapyIdentifying 24 h variation in the pharmacokinetics of levofloxacin: a population pharmacokinetic approach.Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function.Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureusBactericidal activity of the combination of levofloxacin with rifampin in experimental prosthetic knee infection in rabbits due to methicillin-susceptible Staphylococcus aureus.Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infectionPharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization.Sex-related differences in the pharmacokinetics of oral ciprofloxacin.Pharmacokinetics of intravenously administered levofloxacin in men and women.Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial.Penetration of levofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses.High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats.Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers.
P2860
Q33559026-3B69BEF7-0F7A-4D61-8C48-3201DB3DEDA6Q33836597-B680DDEF-4C37-4799-88A7-CAAF4E22E699Q34307105-5936EBFA-D817-4EFF-BA25-35FECBB79911Q34551560-144565AF-3841-455E-92B2-00D8BD34A05DQ34680572-38805375-1A13-4BE1-AE24-F8F83CE36129Q35065775-5705C307-5EDB-465F-806D-1E4EA09C1DEFQ35166134-8272B0E7-B7C7-4EE6-81AE-248828576A82Q36911111-E16C7855-5B8F-4A3B-BB48-5C4BD4A9C904Q37115679-FA102978-2C32-4CC3-801A-8236CBF84C65Q37625098-606F0D73-E8DC-45E5-BD1E-E29431329AB2Q37747381-0B0912B6-45D6-40ED-BA5E-2A8A068EE2E0Q37846092-BDC29D99-2371-4BB3-8712-B1D69E39B507Q37995676-7A02B0CB-65D1-4E3D-837D-C4BA66D85F2FQ38369608-4CEED02E-DD67-4AF4-A5D4-39C646772F46Q38842229-5484CC04-B20A-41E0-AE80-A488EFBDF786Q40225657-2F3F2825-A598-4D2E-A471-47B7437471BAQ40392507-0D5E6335-8691-436B-939E-CF91666F35BFQ40903164-9EB3724D-5B1C-4668-9BF0-32EAC48C69FAQ41833286-10324903-35D3-44A0-A80D-26C9F3FDCB91Q41913615-49F12B36-C9A6-48F2-93B3-3940644EEB3AQ42042948-AD0F4F10-04C7-4E08-9C07-AF1DF0487E13Q42633876-698D57E5-B98C-4BFE-BF02-67C3506FFD21Q42668977-EF797CA1-DF18-48FC-8C6E-744D705536BAQ42681448-5A55820C-370B-446D-9FE0-74D494BDD5C6Q43970889-09171C43-634C-4D6C-BAE9-AC3E7589633CQ44573499-50F874FC-2473-4306-A8C2-A14621EC9614Q46623734-18161BDB-EDF5-40BC-BBE6-2566E1EAD635Q46704604-922CFFD8-357F-4E34-B8E3-AC859C40EE38Q53384595-DADD7DA5-39B2-4F2B-9D6D-1AC3C8B609D8
P2860
Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Safety and pharmacokinetics of ...... loxacin in healthy volunteers.
@ast
Safety and pharmacokinetics of ...... loxacin in healthy volunteers.
@en
type
label
Safety and pharmacokinetics of ...... loxacin in healthy volunteers.
@ast
Safety and pharmacokinetics of ...... loxacin in healthy volunteers.
@en
prefLabel
Safety and pharmacokinetics of ...... loxacin in healthy volunteers.
@ast
Safety and pharmacokinetics of ...... loxacin in healthy volunteers.
@en
P2093
P2860
P1476
Safety and pharmacokinetics of ...... loxacin in healthy volunteers.
@en
P2093
P2860
P304
P356
10.1128/AAC.45.7.2122-2125.2001
P407
P577
2001-07-01T00:00:00Z